Europe’s medical devices industry saw a rise of 12.50% in cross border deal activity during May 2022

Europe’s medical devices industry saw a rise of 12.50% in cross border deal activity during May 2022, when compared with the last 12-month average, led by Straumann’s $138.06m acquisition of SunshineSmile, according to GlobalData’s deals database.

 

A total of 27 medical devices industry cross border deals worth $356.7m were announced for the region in May 2022, against the 12-month average of 24 deals.

Of all the deal types, M&A saw most activity in May 2022 with 14 transactions, representing a 51.9% share for the region.

In second place was venture financing with nine deals, followed by private equity deals with four transactions, respectively capturing a 33.3% and 14.8% share of the overall cross border deal activity for the month.

In terms of value of cross border deals, M&A was the leading category in Europe’s medical devices industry with $177.75m, while venture financing and private equity deals totalled $153.5m and $25.5m, respectively.

Europe medical devices industry cross border deals in May 2022: Top deals

The top five medical devices cross border deals accounted for 80.3% of the overall value during May 2022.

The combined value of the top five medical devices cross border deals stood at $286.51m, against the overall value of $356.7m recorded for the month.

The top five medical devices industry cross border deals of May 2022 tracked by GlobalData were:

1) Straumann $138.06m acquisition deal with SunshineSmile

2) The $75.34m venture financing of Diabeloop by Innovacom,LBO France and Terumo

3) AlbionVC,Athyrium Capital Management and DNV Group $25.5m private equity deal with uMotif

4) The $24.68m acquisition of Rigenerand by Evotec

5) Evonik Venture Capital,Fountain Healthcare Partners,LSP Health Economics Fund,Orchestra BioMed and Panakes Partners $22.92m venture financing deal with Vivasure Medical